Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)
Hirota, T.; Takeuchi, M.; Iwata, A.; Kitagawa, S.; Sato, T.; Konno, K.; Sawada, K.; Kobayashi, S.; Hamaguchi, N.; Agata, H.; Katano, N.; Fujimoto, T.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 25(3): 385-390
1998
ISSN/ISBN: 0385-0684 PMID: 9492832 Document Number: 493591
Ifosfamide, Carboplatin and Etoposide (ICE) therapy was used to treat 4 patients, 2 with refractory osteosarcoma, and one each with relapsed brain tumor and newly diagnosed brain tumor. ICE therapy was administered in doses of Ifosfamide 1,800 mg/m2 x 5, Carboplatin 400 mg/m2 x 2 and Etoposide 100 mg/m2 x 5. A total of 30 courses were administered. Two cases of osteosarcoma had a stable disease (range, 3-9 months) and 2 cases of brain tumor had a complete response by magnetic resonance imaging. Moderate or severe toxicity evaluated on a per course basis included: neutropenia 83%, thrombocytopenia 93%, fever 30%, hepatotoxicity 3%, and hemorrhagic cystitis 3%. The median time to hematologic recovery was 20 days. ICE therapy is highly effective for the treatment of refractory or recurrent solid tumors with acceptable toxicity.